Experimental HIV Drugs
Experimental HIV Drugs
CROI 2012: Tenofovir Pro-drug GS-7340 Shows Good Efficacy, Safety, and Suitability for Coformulation
- Details
- Category: Experimental HIV Drugs
- Published on Thursday, 08 March 2012 00:00
- Written by Liz Highleyman
GS-7340, a pro-drug of tenofovir that reaches higher concentrations in cells, was shown to have superior efficacy and may be more suitable for inclusion in coformulated regimens, researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this week in Seattle.
Dolutegravir Expanded Access Begins, but Advocates Urge Caution
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 06 March 2012 00:00
- Written by Liz Highleyman
ViiV Healthcare and Shionogi have opened an expanded access program (EAP) for their investigational HIV integrase inhibitor dolutegravir for treatment-experienced patients. The drug offers a new option for people with extensively drug-resistant virus, but activists caution that dolutegravir should not be used as a single active agent, as this could lead to resistance that limits its usefulness.
Elvitegravir Continues to Look Good at 2 Years
- Details
- Category: HIV Treatment
- Published on Tuesday, 13 December 2011 00:00
- Written by Press Release
Gilead Sciences announced last week that its experimental integrase inhibitor elvitegravir continued to suppress HIV viral load as well as raltegravir (Isentress) in combination with a boosted protease inhibitor at 96 weeks in a Phase 3 study.
Gilead Starts Phase 2 Trial of Tenofovir Pro-drug GS-7340
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 27 January 2012 00:00
- Written by Press Release
Gilead Sciences this week announced the start of a new Phase 2 clinical trial that will compare an all-in-1 combination pill containing GS-7340 -- a pro-drug of tenofovir (Viread, also in the Truvada and Atripla coformulations) that can be taken in lower doses -- versus the experimental Quad combo containing the same drugs with tenofovir itself.
Cobicistat Booster Works as Well as Ritonavir at 48 Weeks
- Details
- Category: HIV Treatment
- Published on Tuesday, 06 December 2011 00:00
- Written by Gilead Sciences
Gilead Sciences this week announced the latest results from a Phase 3 trial of its experimental boosting agent cobicistat, which raises levels of other drugs processed by the same enzymes in the liver. The study found that cobicistat worked as well as ritonavir (Norvir) as a booster for atazanavir (Reyataz) over 48 weeks.
Web Design and Development by